Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
复制标题
DOI：
10.1186/s12933-016-0480-8
复制
发表时间：
2016-12-03
影响因子：
9.3
通讯作者：
Ceriello A
中科院分区：
文献类型：
--
作者：
Rizzo M;Rizvi AA;Patti AM;Nikolic D;Giglio RV;Castellino G;Li Volti G;Caprio M;Montalto G;Provenzano V;Genovese S;Ceriello A
利拉鲁肽是一种GLP-1类似物，在2型糖尿病（T2 DM）患者中发挥多种有益的非血糖效应，如对体重、血压、血脂和炎症标志物的影响。然而，利拉鲁肽对代谢综合征（MetS）受试者心血管（CV）风险标志物的影响在很大程度上仍然未知。我们在此探讨了其对T2 DM受试者中MetS的各种心脏代谢风险标志物的影响。我们进行了一项为期18个月的前瞻性真实世界研究。根据AHA/NHLBI标准，所有受试者均患有T2 DM和MetS。排除有重大CV事件史的受试者。纳入了121例T2 DM和MetS受试者（71例男性和50例女性;平均年龄：62 ± 9岁），这些受试者未接受过基于肠促胰岛素的治疗，仅接受二甲双胍治疗。在整个研究中，利拉鲁肽（1.2 mg/天）添加至二甲双胍（1500-3000 mg/天）。在基线和此后每6个月收集用于代谢参数的空腹血浆样本，并通过B型实时超声评估颈动脉内膜中层厚度（cIMT）。在18个月的随访中，腰围、体重指数、空腹血糖、HbA 1c、总胆固醇和LDL胆固醇、甘油三酯和cIMT显著降低。相关性分析显示cIMT的变化与甘油三酯之间存在显著相关性（r = 0.362; p < 0.0001）。MetS患病率在研究期间显著降低，并且26%的受试者在18个月后不再符合MetS的标准。在一项真实世界研究中，利拉鲁肽可改善MetS受试者的心脏代谢风险因素。 试用注册ClinicalTrials.gov：NCT 01715428。
Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500–3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter. There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months. Liraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.
登录
查看更多内容
影响因子：
4.8
作者：
Inoue K;Maeda N;Fujishima Y;Fukuda S;Nagao H;Yamaoka M;Hirata A;Nishizawa H;Funahashi T;Shimomura I
通讯作者：
Shimomura I
DOI：
10.1038/ijo.2011.158
发表时间：
2012-06
期刊：
International journal of obesity (2005)
影响因子：
--
作者：
Astrup A;Carraro R;Finer N;Harper A;Kunesova M;Lean ME;Niskanen L;Rasmussen MF;Rissanen A;Rössner S;Savolainen MJ;Van Gaal L;NN8022-1807 Investigators
通讯作者：
NN8022-1807 Investigators
影响因子：
7.7
作者：
Noyan-Ashraf MH;Momen MA;Ban K;Sadi AM;Zhou YQ;Riazi AM;Baggio LL;Henkelman RM;Husain M;Drucker DJ
通讯作者：
Drucker DJ
利拉鲁肽作为胰岛素附加治疗与增加胰岛素剂量对控制不佳的2型糖尿病和腹型肥胖的中国受试者的疗效和安全性比较
影响因子：
9.3
作者：
Li, Chun-jun;Li, Jing;Yu, De-min
通讯作者：
Yu, De-min
影响因子：
8.3
作者：
Corrado, E;Rizzo, M;Novo, S
通讯作者：
Novo, S